Company Presentation

Vandria develops novel small molecules induce mitophagy to treat age-related and chronic diseases.
The company is in the the IND-enabling stage targeting:
• CNS: Mild Cognitive Impairment, ALS
• Muscle: Sporadic Inclusion Body Myositis
• Other: Immuno-oncology, IPF, NASH

Vandria is seeking additional investors to complete its Series A financing round of EUR 14 million led by ND Capital. We also seek partners for our new ferroptosis program.